Treatment with IVIG and glucocorticoids, through their immunomodulatory effects, reduces proinflammatory cytokine synthesis (IL-1β, IL-6, TNF-α), thereby lowering systemic inflammation, stabilizing vascular permeability, and maintaining renal perfusion, potentially decreasing AKI risk [3,22]. This evidence concerns the gene TNF and acute kidney injury.